Advanced in Peripheral Neuropathy

Delvys Abreu-Rodriguez

Las Palmas De Gran Canaria, CN, ES 
Advanced in Peripheral Neuropathy
Las Palmas De Gran Canaria, CN, ES 
OverviewLocationsClinical Research

Overview

Delvys Abreu-Rodriguez practices in Las Palmas De Gran Canaria, Spain. Abreu-Rodriguez is rated as an Advanced expert by MediFind in the treatment of Peripheral Neuropathy. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Their clinical research consists of co-authoring 118 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles in the study of Peripheral Neuropathy.

Locations

Las Palmas De Gran Canaria, CN, Spain
Other Locations
Barcelona, CT, Spain
Hospital Universitari Dr. Josep Trueta, Las Palmas De Gran Canaria And Hospital Universitario Dr. Balmis Alicante, Alicante, VC, Spain
Santiago De Compostela, GA, Spain
Madrid, MD, Spain
Gran Canaria, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2

118 Total Publications

Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].
Journal: JTO clinical and research reports
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Abreu-Rodriguez's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile